Ligand to Report Third Quarter Results on November 5th
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (LGND) announced today plans to report third quarter 2012 financial results on Monday, November 5, 2012. Ligands President and CEO, John L. Higgins, Executive Vice President and COO, Matt Foehr and Vice President of Finance and CFO, John Sharp will host the conference call.
Third Quarter Earnings Call
|What:||Ligand Pharmaceuticals conference call to discuss financial results and provide general business updates.|
|When:||Monday, November 5, 2012|
|Time:||1:30 p.m. Pacific time (4:30 p.m. Eastern time)|
Conference call and replay accessible at www.ligand.com.
|Conference Call:||(877) 407-4019, passcode: Ligand|
|(201) 689-8337 outside the U.S.|
|Replay:||(877) 660-6853, passcode: 401229|
|(201) 612-7415 outside the U.S.|
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company that develops and acquires assets it believes will generate royalty revenues and, under its lean corporate cost structure, produce sustainable profitability. Ligand has a diverse asset portfolio addressing the unmet medical needs of patients for a broad spectrum of diseases including thrombocytopenia, multiple myeloma, diabetes, hepatitis, muscle wasting, dyslipidemia, anemia, and osteoporosis. Ligands Captisol® platform technology is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Merck, Pfizer, Eli Lilly & Company, Baxter International, Bristol-Myers Squibb, Celgene, Onyx Pharmaceuticals, Lundbeck Inc., The Medicines Company, Curis, Inc. and Rib-X Pharmaceuticals. Please visit www.captisol.com for more information on Captisol. For more information on Ligand, please visit www.ligand.com.
Follow Ligand on Twitter @Ligand_LGND.
Ligand Pharmaceuticals Incorporated
John Higgins, President and CEO
Jennifer Capuzelo, Investor Relations
Source: Ligand Pharmaceuticals IncorporatedCopyright Business Wire 2012